CVM

#4490
Cel-Sci Corporation Common Stock
1.5 4 USD
+3.36%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
1.53
1.57
Rango anual
0.01
5.15
Cambio diario
+3.36%
Variación mensual
-47.62%
Variación en los últimos 6 meses
-70.10%
Cambio anual
-70.10%
Cierres anteriores
1.4 9
Open
1.5 5
Mínimo
1.5 3
High
1.5 7
Volumen
15
Ver el calendario completo Full chart

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 13.08 M
  • Employee 44
  • Founded N/A
  • CEO N/A
  • Website www.cel-sci.com
  • Headquarter Colorado, United States
  • FIGI BBG000H5G6L5
  • Industry Biotecnología
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-1.47
Relación precio/flujo de caja
-57.5

Cel-Sci Corporation Common Stock

Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products. Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint.

Noticias